Viridian Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Viridian Therapeutics generated cash of -$184,170,000, which is less than the previous year. Cash used in financing activities reached the amount of $225,670,000 last year. Net change in cash is therefore -$52,752,000.
Cash Flow
| 2014 | -2.21M | -274K | 7.39M |
|---|---|---|---|
| 2015 | -6.89M | -95K | 12.70M |
| 2016 | -7.23M | -3K | -257K |
| 2017 | -28.16M | 1.03M | 52.47M |
| 2018 | -26.84M | -29.90M | 41.91M |
| 2019 | -36.05M | 28.22M | 70K |
| 2020 | -29.77M | -50.48M | 101.31M |
| 2021 | -54.58M | -74.29M | 125.27M |
| 2022 | -93.83M | -115.12M | 322.24M |
| 2023 | -184.17M | -94.25M | 225.67M |
VRDN Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 155.57M | 42.29M | 45.89M | 24.84M | 32.60M | 47.44M | 22.10M | 10.83M | 5.11M | 209K |
Operating activities | ||||||||||
Net income | -237.73M | -129.87M | -79.41M | -110.71M | -41.87M | -32.70M | -26.51M | -12.67M | -11.32M | -7.89M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 522K | 255K | 120K | 239K | 288K | 281K | 308K | 189K | 184K | 144K |
Stock-based compensation expense | 67.17M | 19.76M | 14.46M | 3.64M | 3.97M | 0 | 2.40M | 2.11M | 3.01M | 4.29M |
| Deferred income tax benefit | 67.17M | 19.76M | 14.46M | 3.64M | 3.97M | 0 | 2.40M | 2.11M | 3.01M | 4.29M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 349K | -451K | 99K | -84K | 1.43M | -1.43M | -130K | 694K | -271K |
Inventories | 0 | -349K | 451K | 0 | 0 | -57.79M | -50.9M | 123K | -8K | 178K |
Accounts payable | -12.04M | 11.52M | 1.65M | -426K | 525K | -335K | -101K | 2.02M | 633K | 383K |
Cash generated by operating activities | -184.17M | -93.83M | -54.58M | -29.77M | -36.05M | -26.84M | -28.16M | -7.23M | -6.89M | -2.21M |
Investing activities | ||||||||||
Purchases Of Investments | -407.88M | -223.26M | -188.43M | -81.80M | -32.69M | -62.46M | 0 | -1M | 0 | 0 |
Investments In Property Plant And Equipment | -898K | -797K | -338K | -42K | -84K | -445K | -246K | -3K | -123K | -266K |
Acquisitions Net | 0 | 114.32M | 79K | 29.37M | -28.31M | 0 | 1.28M | 0 | 0 | 0 |
Cash generated by investing activities | -94.25M | -115.12M | -74.29M | -50.48M | 28.22M | -29.90M | 1.03M | -3K | -95K | -274K |
Financing activities | ||||||||||
Common Stock Issued | 125.06M | 291.87M | 114.24M | 25.10M | 2.48M | 0 | 48.56M | 16.30M | 13.09M | 6.64M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -44K | 0 | 0 | 0 | -173K | -363K | 0 |
Repayments of term debt | 15M | 5M | 0 | -10.29M | -2.33M | 0 | 5.33M | -84K | -76K | -42K |
Cash used in financing activities | 225.67M | 322.24M | 125.27M | 101.31M | 70K | 41.91M | 52.47M | -257K | 12.70M | 7.39M |
Net Change In Cash | -52.75M | 113.28M | -3.59M | 21.05M | -7.76M | -14.83M | 25.33M | -7.49M | 5.71M | 4.91M |
Cash at end of period | 102.82M | 155.57M | 42.29M | 45.89M | 24.84M | 32.60M | 47.44M | 3.34M | 10.83M | 5.11M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |